Impact of the aberrant right hepatic artery on local recurrence of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy
Author:
Nakajima Takayoshi,
Ikuta Shinichi,
Nakamura Ikuo,
Aihara Tsukasa,
Kasai Meidai,
Iwama HideakiORCID,
Fujimoto Yasuhiro,
Hatano EtsuroORCID,
Yamanaka Naoki
Reference38 articles.
1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014
2. Pancreatic cancer;Vincent;Lancet,2011
3. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomized, non-inferiority trial (JASPAC 01);Uesaka;Lancet,2016
4. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial;Neoptolemos;Lancet,2017
5. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma;Groot;Ann Surg,2018
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献